What is the mechanism of action for Durlaza?

Durlaza is formulated as an extended-release version of aspirin, which allows for a slower and prolonged release of the active ingredient in the body. This mechanism is particularly beneficial for providing a steady state of medication, leading to improved adherence to therapy and sustained antiplatelet effects over an extended period.

Unlike standard aspirin formulations that may release the drug quickly, Durlaza’s extended-release profile is designed to maintain appropriate levels of aspirin in the bloodstream, helping to reduce the risk of cardiovascular events by inhibiting platelet aggregation over time. This mechanism is essential in conditions where ongoing antiplatelet therapy is indicated, such as in patients with a history of heart attacks or stroke.

The other options, while related to aspirin and blood thinners, do not accurately describe the specific action of Durlaza. For instance, non-steroidal anti-inflammatory drugs primarily focus on pain and inflammation rather than antiplatelet actions, and blood thinners like Warfarin work via different mechanisms that involve anticoagulation rather than direct inhibition of platelet activity.